BioSpace News Archive

Charles River will use its strengths to help develop potential drug candidates across Takeda’s four core therapeutic areas—oncology, gastroenterology, neuroscience and rare disease.

What’s New at the J.P. Morgan Life Healthcare Conference?

Exscientia, the leading Artificial Intelligence -driven drug discovery company, announced today that it has entered a collaboration with Bayer AG that aims to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology.

Following the acquisition and integration of former Samsung subsidiary Nexus Dx Inc., sphingotec becomes a fully integrated diagnostic solutions provider

On 6 December 2019, Recipharm AB, through its directly wholly-owned subsidiary Recipharm Holdings Limited, published an offer document setting out the full terms and conditions of its recommended cash offer to acquire the entire issued and to be issued share capital of Consort Medical plc.

The deal will increase the availability of next-generation sequencing-based in vitro diagnostic (IVD) tests on Illumina’s diagnostic sequencing systems.

Gilead Sciences is boosting support for a Bay Area startup looking to develop a new class of therapies for autoimmune diseases.

The company has suggested that it plans to undercut both Biogen and Novartis on price in order to make up for being third-to-market.

Grey Wolf targets ERAP antigen presentation pathways with the aim of ‘illuminating’ non-responsive tumors for attack and destruction by the immune system

With a shared vision to be a catalyst for Canadian life sciences leading the world, adMare BioInnovations, Canada’s Global Life Sciences Venture, and Accel-Rx, Canada’s Health Sciences Accelerator, announced they are bringing their respective capabilities and resources together under adMare to create a world leading organization.